COAs
Below are Certificates of Analysis for selected ingredients.
Awards
The 2024 Outstanding Paper Award recognized the published NMN clinical study.
Human Trial
A visual summary of the randomized AbinoNutra™ NMN study; publication details appear below.
Clinical Trials
Three human research programs involving Abinopharm or AbinoNutra study material are listed below.
Abinopharm NMN Trial
A randomized, multicenter, double-blind, placebo-controlled study sponsored by Abinopharm, Inc. Eighty adults aged 40–65 completed 60 days of placebo or 300, 600, or 900 mg of NMN per day. Lin Yi of Abinopharm served as study chair.
One clinical trial, three published analyses:
Exercise Recovery
An independent university study used AbinoNutra™ NMN as the study material. Eleven young men completed a randomized, placebo-controlled crossover study using 1,200 mg per day for seven days. Results were mixed: NMN reduced some inflammatory signaling while also suppressing the expected post-exercise rise in muscle mitochondrial content. No author was affiliated with Abinopharm.
PROMETHEUS
An eight-week, single-arm feasibility study of a personalized lifestyle and nutraceutical program in 20 adults aged 50–80. Participants with lower aerobic capacity received AbinoNutra™ NMN at 300 mg per day. The study included an Abinopharm-affiliated author. Recruitment and final visits are complete, and biomarker analysis is ongoing. The current publication is a protocol; efficacy results have not yet been published.
